# A(H7N9) VLP Antigen Dose-Ranging Study With Matrix-M1™ Adjuvant

> **NCT02078674** · PHASE1,PHASE2 · COMPLETED · sponsor: **Novavax** · enrollment: 610 (actual)

## Conditions studied

- Influenza (Pandemic)

## Interventions

- **BIOLOGICAL:** Monovalent Avian Influenza VLP (H7N9)
- **BIOLOGICAL:** Matrix-M1™ adjuvant
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT02078674
- **Lead sponsor:** Novavax
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-03
- **Primary completion:** 2015-07
- **Final completion:** 2015-07
- **Target enrollment:** 610 (ACTUAL)
- **Last updated:** 2016-09-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02078674

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02078674, "A(H7N9) VLP Antigen Dose-Ranging Study With Matrix-M1™ Adjuvant". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02078674. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*